Analyst Coverage

LBT Innovations is resetting expectations with investors regarding the sale process for its automated plate processing instrument, called APAS Independence. Read the full report here.

PAC Partners Analyst Report - Analyst report from PAC Partners following the first sale of APAS Independence to St Vincent's Hospital in Melbourne

The Investment Proposition Does the Means Justify the End? Brent Barnes CEO LBT Innovations addresses the topic at the 14th Biotech Summit

Bioshares Analyst Report - Targets for LBT Innovations based on sales of the APAS Independence instrument and ongoing software licences.

LBT’s APAS® received regulatory approval and patents over the last 18 months. Its first evaluation trial at St Vincent Hospital was successfully completed.

Bioshares Analyst Report following LBT Innovations installation of its first APAS Independence instrument in Melbourne, at St Vincent's Hospital.

Robotics is a hot investment theme and LBT has been riding the wave of interest with its device to automate the processing and analysis of biological samples.

Under the Radar Report Biotech Special - Tim Boreham's sector run-down on opportunities to make money from the makers of devices and diagnostic tools.

WoundVue is a hand-held device capable of interpreting tissue types and providing surface area, volume and depth measurements.

LBT Innovations has completed the self-certification process for CE Marking for its APAS Independence launching by year’s end.